Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | IAPP | P10997 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398316 | 0.82 | ADAMTS5 (0.42) | SMN1; SMN2MAPTNPC1RAB9AHSP90AA1 | |
| SCHEMBL9659322 | 0.81 | RAB9A (0.42) | SMN1; SMN2MAPTALOX15TSHRHSD17B10 | |
| SCHEMBL6297776 | 0.78 | SMN1; SMN2 (0.38) | SMN1; SMN2MAPTALOX15TSHRHSD17B10 | |
| SCHEMBL12753492 | 0.78 | SMN1; SMN2 (0.36) | SMN1; SMN2MAPTALOX15TSHRHSD17B10 | |
| SCHEMBL1398311 | 0.76 | ADAMTS5 (0.40) | SMN1; SMN2MAPTALOX15TSHRHSD17B10 | |
| SCHEMBL1846533 | 0.76 | RAB9A (0.41) | SMN1; SMN2MAPTALOX15TSHRHSD17B10 | |
| SCHEMBL129530 | 0.75 | — | — | |
| SCHEMBL12530273 | 0.74 | ALDH1A1 (0.44) | SMN1; SMN2MAPTTSHRNPC1RAB9A | |
| SCHEMBL634118 | 0.74 | — | — | |
| SCHEMBL5427662 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299064-B2 | Fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof | AJINOMOTO CO., INC. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20110160191-A1 | NEW FUSED POLYCYCLIC COMPOUNDS HAVING A HETEROCYCLIC RING(S) AND PHARMACEUTICAL USE THEREOF | AJINOMOTO CO., INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7928101-B2 | Fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof | AJINOMOTO CO., INC. (JP) | 2011-04-19 | — | — | US | disclosed |
| EP-1112269-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015634-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160191-A1 | NEW FUSED POLYCYCLIC COMPOUNDS HAVING A HETEROCYCLIC RING(S) AND PHARMACEUTICAL USE THEREOF | SLC2A4, SLC2A1, SLC2A3 | SMN1; SMN2 3891/4885MAPT 2800/4885ALOX15 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.